GHRP-6 Peptide – User Manual & Dosage Protocol Guide

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide studied for its ability to stimulate endogenous growth hormone (GH) release via ghrelin receptor (GHS-R1a) activation.

Research Applications

• GH pulsatility and IGF-1 pathway studies
• Body composition and recovery models
• Appetite and ghrelin signaling research
• Tissue repair and regenerative biology models

Disclaimer: GHRP-6 is for research and experimental use only and is not FDA-approved for therapeutic use in this context.

Lyophilized Powder

Freeze-dried GHRP-6 intended for reconstitution prior to use in research settings.

Reconstituted Solution

Prepared liquid form used for subcutaneous (SC) research injection after proper preparation.

GHRP-6 is studied for its ability to:

• Activate growth hormone secretagogue receptors (GHS-R1a)
• Increase pulsatile GH release from the pituitary
• Elevate downstream IGF-1 signaling
• Influence appetite/ghrelin pathways in experimental systems

Effects are primarily observed in preclinical and investigational protocols.

Subcutaneous (SC) – Standard Research Model

Typical research protocols use 100–300 µg per administration, generally 1–3 times daily. It is often scheduled before sleep or prior to specific study windows.

Combination Research

Some studies use 100–200 µg per administration, typically 1–3 times daily, and frequently pair it with GHRH analogs in growth hormone pulse models.

Administration Method

Most research protocols utilize subcutaneous (SC) administration for controlled and consistent delivery.

Important

There is no approved human dosage outside regulated clinical use. The ranges above reflect common research patterns only.

Initiation

A 1–2 week phase used to evaluate response and tolerance during the early stage of the study.

Active Study Phase

The 6–12 week primary phase focused on observing growth hormone and IGF-1 outcomes.

Rest Period

A 2–4 week interval between study cycles to allow physiological systems to reset.

Note

Cycle length may vary depending on the study design and research endpoints.

Supplies

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.

• Example: 5 mg vial + 2 mL → 2.5 mg/mL

1. Swirl gently to dissolve (do not shake).
2. Refrigerate at 2–8°C after reconstitution.
3. Use within 2–4 weeks or per protocol.

Subcutaneous Injection Model

• Common sites: abdomen, thigh, upper arm
• Clean site prior to administration
• Inject slowly and rotate sites to minimize irritation

Store in a cool, dry environment to maintain stability, with a shelf life of up to 12 months.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve product quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate contamination or degradation.

• Research use only
• Not for therapeutic application
• Possible research observations: injection-site irritation, transient flushing, increased appetite
• Maintain sterile handling technique
• Keep out of reach of children

Human safety outside controlled research is not established.

Peptide: GHRP-6
Category: Hormone Therapy / Recovery Research
Delivery: Subcutaneous research model
Typical Investigational Range: 100–300 µg, 1–3× daily
Cycle: 6–12 week study designs
Storage: Refrigerated after reconstitution